Home » Clinical Trials » Leukemia » NCT04303520
NCT04303520

A Phase I Clinical Trial of T-Cells Targeting CD19 and CD22 for Subjects With CD19-positive Acute Lymphoblastic Leukemia

Study Summary

The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/CD22 bispecific chimeric antigen receptors (CARs) T cell therapy for CD19-positive Acute Lymphoblastic Leukemia.

Want to learn more about this trial?

Request More Info

Interventions

anti-CD19/CD22 CAR-T cellsBIOLOGICAL
Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
FludarabineDRUG
30mg/m2/d
CyclophosphamideDRUG
500mg/m2/d

Study Locations

FacilityCityStateCountry
Henan Province of TCMZhengzhouHenanChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026